ORAMED PHARMACEUTICALS INC

Oramed Pharmaceuticals shares dip 0.48% as market volatility hits, yet its oral insulin platform and pending regulatory milestones keep upside potential high.

Oramed Pharmaceuticals (ORMP) trades near $4.12, falling 0.24% on March 23, 2026, amid a 12.84% monthly decline; an Israeli pharma innovator in oral drug delivery.

Oramed (ORMP) climbs 2.22 % as investors eye its oral insulin capsule launch—potential catalyst amid modest market gains and a low 200‑day moving‑average breakout.